Heterogeneity in Cardiovascular Death or Hospitalization for Heart Failure Benefits with Flozins is Linked to Weight
Pooled result · CV death or hHFResult — go to the resultHazard ratio 0.77 95% CI 0.70–0.85Authors' conclusion
The results of this meta-regression analysis suggest that the beneficial effects of SGLT-2is in reducing CV deaths and hHFs are related to the weight variable.
Study context
- Population
- Patients with T2DM in CV outcome trials of SGLT2 inhibitors
- Participants
- 46,969 patients · 5 studies
- Comparison
- SGLT2 inhibitors vs placebo
- Outcome
- CV death or hospitalization for HF
Methodological detailsrandom-effects model, Cochrane risk of bias tool used to assess study quality
- Random-effects model
- Cochrane risk of bias tool used to assess study quality
Pooled result
CV death or hHF
Hazard ratio
0.77
95% CI 0.70–0.85
SGLT-2i vs Placebo
HR 0.77 (95% CI 0.70–0.85)
As reported in the abstract
Further pooled results
Meta-regression: weight as moderator of CV death or hHF benefit
- Significant correlation of outcomes with weight variable
- P < 0.01
- Weight differential explained entire variance in true effect size
- R2 = 1.00
Original publication
Heterogeneity in Cardiovascular Death or Hospitalization for Heart Failure Benefits with Flozins is Linked to Weight. ESC Heart Fail. Published 27 January 2023. doi:10.
Summarised from the published abstract; every number is checked against it